Chongqing Daxin Pharmaceutical

Chongqing Daxin Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Established in 1941, the company has become a global leader in fermentation-based and synthetic drug production, with a specific focus on statins and immunosuppressants. Daxin is a major supplier of lovastatin, simvastatin, and mycophenolate mofetil, serving international markets including the United States, Europe, and Japan. Operating as a core subsidiary of PKU HealthCare, the company maintains multiple facilities with US FDA and EU GMP certifications to ensure high-quality manufacturing standards for its diverse product portfolio.